Mothers against decapentaplegic homolog 3
Mothers against decapentaplegic homolog 3 (SMAD3) is a protein that in humans is encoded by the SMAD3 gene. It is a member of the SMAD family of proteins, which are part of the TGF-beta signaling pathway. This pathway is important for regulating cell growth, cell differentiation, and apoptosis (programmed cell death), playing a critical role in the development and maintenance of tissues and organs. SMAD3 specifically transmits signals from the cell surface to the nucleus following activation by TGF-beta ligands.
Function
SMAD3 is involved in the intracellular signaling processes of the TGF-beta superfamily of cytokines. Upon TGF-beta ligand binding to the TGF-beta receptor, SMAD3 is phosphorylated by the receptor kinase. Phosphorylated SMAD3 then forms a complex with SMAD4, and this complex translocates to the nucleus where it can regulate the transcription of target genes involved in various cellular processes.
Clinical Significance
Alterations in the SMAD3 gene or its signaling pathway can lead to a variety of diseases. Mutations in SMAD3 have been associated with an increased risk of certain cancers, including colorectal cancer and lung cancer. Additionally, aberrant SMAD3 signaling is implicated in fibrotic diseases, such as pulmonary fibrosis, due to its role in the regulation of extracellular matrix production. SMAD3 is also involved in the pathogenesis of cardiovascular diseases, including aortic aneurysm, through its effects on vascular smooth muscle cell proliferation and differentiation.
Genetic Studies
Research has identified several polymorphisms within the SMAD3 gene that are linked to an increased susceptibility to various diseases. These genetic studies highlight the importance of SMAD3 in human health and disease, and suggest that targeting the SMAD3 signaling pathway could be a therapeutic strategy for treating diseases associated with its dysregulation.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
